Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, United States; Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Salmovska 1, Prague 2 12000, Czech Republic.
Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, Brno CZ-61300, Czech Republic.
J Control Release. 2021 Mar 10;331:246-259. doi: 10.1016/j.jconrel.2021.01.020. Epub 2021 Jan 20.
Despite intensive research efforts and development of numerous new anticancer drugs and treatment strategies over the past decades, there has been only very limited improvement in overall patient survival and in effective treatment options for pancreatic cancer. Current chemotherapy improves survival in terms of months and death rates in pancreatic cancer patients are almost equivalent to incidence rates. It is imperative to develop new therapeutic approaches. Among them, gene silencing shows promise of effectiveness in both tumor cells and stromal cells by inhibiting tumor-promoting genes. This review summarizes potential targets for gene silencing in both pancreatic cancer cells and abundant stromal cells focusing on non-viral delivery systems for small RNAs and discusses the potential immunological implications. The review concludes with the importance of multifactorial therapy of pancreatic cancer.
尽管过去几十年来进行了大量的研究工作，并开发了许多新的抗癌药物和治疗策略，但总体患者生存率和胰腺癌的有效治疗选择仅得到了非常有限的改善。目前的化疗可在数月内提高生存率，胰腺癌患者的死亡率几乎与发病率相当。因此，开发新的治疗方法势在必行。其中，基因沉默通过抑制促进肿瘤的基因，在肿瘤细胞和基质细胞中都显示出有效性的潜力。本文综述了胰腺癌细胞和丰富的基质细胞中基因沉默的潜在靶点，重点讨论了非病毒递送系统用于小 RNA 的潜力及其潜在的免疫学意义。本文最后总结了胰腺癌多因素治疗的重要性。
